Shweta Frechette
Family · Stuart, FLNPI 1528558822
Payments from drug & device makers
Across 604 payments — averaging $21.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- Actelion Pharmaceuticals US, Inc.$2K
- GSK$915
- United Therapeutics Corporation$799
- Insmed, Inc.$730
- Regeneron Healthcare Solutions, Inc.$686
- plus $6K from 30 others
What the payments were for
- Food & beverage$13,12899%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 109 | $2,329 |
| Actelion Pharmaceuticals US, Inc. | 66 | $1,949 |
| GSK | 53 | $915 |
| United Therapeutics Corporation | 22 | $799 |
| Insmed, Inc. | 34 | $730 |
| Regeneron Healthcare Solutions, Inc. | 24 | $686 |
| Boehringer Ingelheim | 39 | $640 |
| Inogen, Inc. | 48 | $626 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $626 |
| Mylan Specialty L.p. | 18 | $369 |
| Amgen | 19 | $360 |
| Mallinckrodt Hospital Products Inc. | 17 | $340 |
| Grifols USA, LLC | 12 | $323 |
| Verona Pharma, Inc. | 12 | $276 |
| Electromed, Inc. | 20 | $276 |
| Pulmonx Corporation | 7 | $255 |
| Merck | 9 | $212 |
| Pfizer | 10 | $206 |
| Baxter Healthcare | 10 | $181 |
| Sanofi | 7 | $169 |
| Advanced Respiratory, Inc | 5 | $140 |
| Genentech USA, Inc. | 6 | $117 |
| Vifor Pharma, Inc. | 4 | $104 |
| Novartis | 4 | $101 |
| Paratek Pharmaceuticals, Inc. | 5 | $87 |
| Philips North America LLC | 5 | $84 |
| Jazz Pharmaceuticals Inc. | 3 | $66 |
| Novo Nordisk | 4 | $59 |
| Johnson & Johnson | 3 | $49 |
| Teva Pharmaceuticals USA, Inc. | 2 | $38 |
| Astellas Pharma US Inc | 2 | $35 |
| ANI Pharmaceuticals, Inc. | 1 | $33 |
| CMP Pharma, Inc. | 1 | $28 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Melinta Therapeutics, LLC | 1 | $22 |
| Amarin Pharma, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CHARTIS CATHETER$137
- ZEPHYR DELIVERY CATHETER$137
- ZEPHYR ENDOBRONCHIAL VALVE$137
- PULMONX CHARTIS TABLET CONSOLE$137
- BREZTRI$136
- FASENRA$136
- TEZSPIRE$136
- NUCALA$125
- Prolastin-C Liquid$124
- TYVASO$112
- AIRSUPRA$104
How this compares
$13,269 in reported general payments places this provider in the 95th percentile of 14,618 family providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 332 | $334,216 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 71 | $65,839 |
| Breo ElliptaFluticasone/Vilanterol | 101 | $54,364 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 54 | $31,997 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 32 | $23,917 |
| EliquisApixaban | 30 | $18,879 |
| SymbicortBudesonide/Formoterol Fumarate | 49 | $14,671 |
| MounjaroTirzepatide | 11 | $11,824 |
| Spiriva RespimatTiotropium Bromide | 14 | $11,177 |
| Advair HfaFluticasone Propion/Salmeterol | 27 | $10,589 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 34 | $4,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 135 | $4,521 |
| Wixela InhubFluticasone Propion/Salmeterol | 38 | $2,373 |
| Montelukast Sodium | 143 | $1,949 |
| Ventolin HfaAlbuterol Sulfate | 19 | $1,046 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $915 | $420,576487 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $2,329 | $80,510120 claims |
| Boehringer IngelheimStiolto Respimat, Spiriva Respimat | $640 | $35,09446 claims |
| PfizerEliquis | $206 | $18,87930 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 14,618 family providers in Florida.
Other family in Stuart
- John HuffakerVenice$8M
- Stephanie MompointMiami$4.5M
- Miguel TrujilloMiami Gardens$4.4M
- Itsel Cardenas RamonMiami$1M
- Lewis HarringtonTampa$954K
- Adam StrosbergFort Lauderdale$859K
- Danielle PharesFt Lauderdale$713K
- David RodriguezHialeah$658K
- Donna OrtizOrlando$417K
- Patrick SzarazMiami$327K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.